NO20075412L - Fremgangsmater og preparater til modulering av hyperstabilisert C-MET - Google Patents

Fremgangsmater og preparater til modulering av hyperstabilisert C-MET

Info

Publication number
NO20075412L
NO20075412L NO20075412A NO20075412A NO20075412L NO 20075412 L NO20075412 L NO 20075412L NO 20075412 A NO20075412 A NO 20075412A NO 20075412 A NO20075412 A NO 20075412A NO 20075412 L NO20075412 L NO 20075412L
Authority
NO
Norway
Prior art keywords
met
hyper
modulating
stabilized
preparations
Prior art date
Application number
NO20075412A
Other languages
English (en)
Norwegian (no)
Inventor
Monica Kong-Beltran
Dineli M Wickramasinghe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075412(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20075412L publication Critical patent/NO20075412L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
NO20075412A 2005-03-25 2007-10-24 Fremgangsmater og preparater til modulering av hyperstabilisert C-MET NO20075412L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25
PCT/US2006/010850 WO2006104911A2 (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Publications (1)

Publication Number Publication Date
NO20075412L true NO20075412L (no) 2007-12-21

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075412A NO20075412L (no) 2005-03-25 2007-10-24 Fremgangsmater og preparater til modulering av hyperstabilisert C-MET

Country Status (18)

Country Link
US (2) US7615529B2 (es)
EP (1) EP1868648B1 (es)
JP (2) JP2008535821A (es)
KR (1) KR20080000613A (es)
CN (1) CN101184506B (es)
AU (1) AU2006229989B2 (es)
BR (1) BRPI0611468A2 (es)
CA (1) CA2599988A1 (es)
ES (1) ES2539790T3 (es)
HK (1) HK1109075A1 (es)
IL (1) IL185708A (es)
MX (1) MX2007011652A (es)
NO (1) NO20075412L (es)
NZ (1) NZ561211A (es)
RU (1) RU2404193C2 (es)
SG (1) SG159547A1 (es)
WO (1) WO2006104911A2 (es)
ZA (1) ZA200707953B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200707953B (en) * 2005-03-25 2009-06-24 Genenthech Inc Methods and compositions for modulating hyperstabilized c-met
EP2257293A2 (en) * 2008-03-06 2010-12-08 Genentech, Inc. Combination therapy with c-met and egfr antagonists
RU2547600C2 (ru) * 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2417159A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
MX2011010158A (es) * 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
EP2421898B1 (en) 2009-04-20 2016-03-16 Oxford BioTherapeutics Ltd Antibodies specific to cadherin-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
EP2496601B1 (en) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methods and composition for secretion of heterologous polypeptides
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
KR20130138802A (ko) * 2010-10-20 2013-12-19 옥스포드 바이오테라퓨틱스 리미티드 항체
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
JP2014530201A (ja) 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
RU2014124842A (ru) * 2011-11-21 2015-12-27 Дженентек, Инк. Очистка анти-с-мет антител
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
CA2941687A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
CN113150147A (zh) 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2019224275A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
BR112021000620A2 (pt) 2018-07-15 2021-04-20 Enochian BioPharma, Inc. métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer
JOP20210233A1 (ar) 2019-02-26 2023-01-30 Janssen Biotech Inc علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met.
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
JP2000510330A (ja) 1996-04-05 2000-08-15 トーマス・ジェファーソン・ユニバーシティ 癌の診断および予後のための方法
CA2258153C (en) 1996-07-03 2004-08-17 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
PL1636593T3 (pl) * 2003-06-06 2009-08-31 Genentech Inc Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2008507252A (ja) * 2003-12-11 2008-03-13 ジェネンテック・インコーポレーテッド Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
AU2006229990A1 (en) 2005-03-25 2006-10-05 Genentech, Inc. C-met mutations in lung cancer
ZA200707953B (en) 2005-03-25 2009-06-24 Genenthech Inc Methods and compositions for modulating hyperstabilized c-met

Also Published As

Publication number Publication date
US8536118B2 (en) 2013-09-17
US20100028337A1 (en) 2010-02-04
EP1868648A2 (en) 2007-12-26
CN101184506B (zh) 2013-07-17
AU2006229989A1 (en) 2006-10-05
JP2012232979A (ja) 2012-11-29
RU2404193C2 (ru) 2010-11-20
WO2006104911A3 (en) 2007-02-22
IL185708A0 (en) 2008-01-06
ES2539790T3 (es) 2015-07-06
NZ561211A (en) 2011-03-31
HK1109075A1 (en) 2008-05-30
AU2006229989B2 (en) 2012-02-02
SG159547A1 (en) 2010-03-30
IL185708A (en) 2014-11-30
CA2599988A1 (en) 2006-10-05
US20060270594A1 (en) 2006-11-30
JP2008535821A (ja) 2008-09-04
KR20080000613A (ko) 2008-01-02
RU2007139452A (ru) 2009-04-27
EP1868648B1 (en) 2015-04-15
BRPI0611468A2 (pt) 2010-09-08
WO2006104911A2 (en) 2006-10-05
MX2007011652A (es) 2007-11-14
ZA200707953B (en) 2009-06-24
US7615529B2 (en) 2009-11-10
CN101184506A (zh) 2008-05-21

Similar Documents

Publication Publication Date Title
NO20075412L (no) Fremgangsmater og preparater til modulering av hyperstabilisert C-MET
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
HK1117746A1 (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
DK1636593T5 (da) Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20075647L (no) Kjemiske forbindelser
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
NO20082191L (no) Forbindelser
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
ME00261B (me) Tweak vezujuća antitijela
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
DK1592786T3 (da) Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE).
NO20081160L (no) Benzimidazoltiofen forbindelser
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
WO2006076736A3 (en) Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
MX2007008723A (es) Polipeptidos de yersinia spp y metodos de uso.
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application